EHVA fosters a multidisciplinary approach to the challenge of developing broadly effective HIV vaccines.

EHVA’s programme primary goals are to:

  • To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
  • To move at least two novel prophylactic vaccine candidates to clinical development
  • To identify immune correlates associated with control of HIV replication following immunological intervention
  • To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials

News

  • EHVA initiates a clinical trial to test a novel therapeutic vaccine and immunotherapy drug

    The European HIV Vaccine Alliance (EHVA) announces the start of the EHVA T01 / ANRS VRI05 trial, with the initiation of screening of participants at the Lausanne University Hospital Switzerland.

    Press release

europa  

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032